文献速递心律失常

基于生物标志物的房颤患者死亡风险评分:ABC死亡风险评分

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
PubMed 文献 · Eur Heart J · 2018-01-01

本研究在抗凝治疗的房颤患者中开发并验证了包含临床信息和生物标志物的ABC死亡风险评分。ABC死亡评分可能有助于房颤患者的整体风险评估。

要点

  • ABC死亡评分包含年龄、NT-proBNP、肌钙蛋白T、GDF-15和心力衰竭史。
  • 评分在推导和验证队列中校准良好,c指数均为0.74。
  • 高ABC死亡评分患者从阿哌沙班治疗中死亡风险降低更明显。

核心结论

  • 基于生物标志物的ABC死亡风险评分在抗凝房颤患者中开发并内外验证,校准良好,可能有助于整体风险评估。

研究设计与样本

  • 在8548例随机接受达比加群或华法林治疗的房颤患者中进行外部验证,随访2.0年。

主要发现

  • 推导队列发生1047例全因死亡,验证队列发生594例全因死亡。
  • 最重要的死亡预测因子为NT-proBNP、肌钙蛋白T、GDF-15、年龄和心力衰竭。
  • ABC死亡评分在推导队列c指数0.74 vs 0.68,验证队列0.74 vs 0.67,均优于全临床变量模型。
  • 高ABC死亡评分患者中阿哌沙班降低死亡率的效果最明显。

关键数值与推荐

  • ABC死亡评分变量权重与Cox模型系数成比例。

临床怎么用

  • ABC死亡评分可用于抗凝房颤患者的死亡风险分层,辅助整体风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In atrial fibrillation (AF), mortality remains high despite effective anticoagulation. A model predicting the risk of death in these patients is currently not available. We developed and validated a risk score for death in anticoagulated patients with AF including both clinical information and biomarkers. METHODS AND RESULTS: The new risk score was developed and internally validated in 14 611 patients with AF randomized to apixaban vs. warfarin for a median of 1.9 years. External validation was performed in 8548 patients with AF randomized to dabigatran vs. warfarin for 2.0 years. Biomarker samples were obtained at study entry. Variables significantly contributing to the prediction of all-cause mortality were assessed by Cox-regression. Each variable obtained a weight proportional to the model coefficients. There were 1047 all-cause deaths in the derivation and 594 in the validation cohort. The most important predictors of death were N-terminal pro B-type natriuretic peptide, troponin-T, growth differentiation factor-15, age, and heart failure, and these were included in the ABC (Age, Biomarkers, Clinical history)-death risk score. The score was well-calibrated and yielded higher c-indices than a model based on all clinical variables in both the derivation (0.74 vs. 0.68) and validation cohorts (0.74 vs. 0.67). The reduction in mortality with apixaban was most pronounced in patients with a high ABC-death score. CONCLUSION: A new biomarker-based score for predicting risk of death in anticoagulated AF patients was developed, internally and externally validated, and well-calibrated in two large cohorts. The ABC-death risk score performed well and may contribute to overall risk assessment in AF. CLINICALTRIALS.GOV IDENTIFIER: NCT00412984 and NCT00262600.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hijazi Z, Oldgren J, Lindbäck J, et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018. PMID: 29069359. doi:10.1093/eurheartj/ehx584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。